Killing two birds with one stone, Gilead Sciences Inc. has granted non-exclusive licenses for remdesivir to Mylan NV, Cipla Ltd., Jubilant Life Sciences Ltd., Hetero Drugs Ltd. and Ferozsons Laboratories Ltd. for 127 developing countries, including several from Asia but excluding China, thus tilting the pricing debate in its favor while creating substantial capacity for its production.
Gilead Licensing Deal Expands Remdesivir Access, Capacity
Mylan, Cipla, Hetero Labs, Jubilant, Ferozsons Labs Get Rights
Gilead’s voluntary licensing of remdesivir to five companies while temporarily charging no royalty and allowing them pricing latitude for 127 developing countries not only expands market access but tilts the pricing debate in Gilead’s favor. It also brings significant potential add-on manufacturing capacity.
